Neurophet and ALZ-NET signal MoU on therapies for Alzheimer’s illness
South Korean AI firm Neurophet has signed a Memorandum of Understanding (MoU) with the Alzheimer’s Community for Therapy and Diagnostics (ALZ-NET) to facilitate imaging monitoring infrastructure for therapies associated to the illness.
The settlement is meant to supply help to healthcare professionals collaborating in ALZ-NET whereas bettering the standard of look after Alzheimer’s sufferers.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra data
The collaboration goals to extend consciousness of the monitoring of amyloid-related imaging abnormalities (ARIA).
Key merchandise on this partnership embody Neurophet Aqua, a mind imaging evaluation device; Neurophet Scale PET, a quantitative resolution for positron emission tomography (PET) picture evaluation; and the Neurophet Aqua AD Plus built-in mind imaging product.
All three options have 510(okay) clearance from the US Meals and Drug Administration (FDA). It’s anticipated that a number of collaborating medical facilities and neuroimaging services will use these instruments for ongoing medical care.
ALZ-NET is sponsored by the Alzheimer’s Affiliation and administered by the American School of Radiology (ACR).
Ana Franceschi, chair of the American School of Radiology’s Neuroradiology Analysis Committee and member of the ALZ-NET Imaging Working Group, stated, “We’re excited to companion with Neurophet to carry their progressive imaging resolution to ALZ-NET areas. Strengthening the imaging infrastructure inside the community is important to offering high-quality care as Alzheimer’s therapy continues to evolve.”
Neurophet co-CEO Jake Junkil Been stated: “With ALZ-NET, Neurophet goals to contribute to the creation of an image-based monitoring infrastructure that’s important within the period of Alzheimer’s therapies. We are going to assist enhance the general high quality of the Alzheimer’s therapy ecosystem within the US.”
In October 2024, Neurophet partnered with biopharma AriBio to develop a platform aimed toward accelerating the analysis of Alzheimer’s illness.
